Página principal > Artículos > Resultados de la búsqueda: Cortés, Javier

Artículos

  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Artículos Encontrados 30 registros  inicioanterior14 - 23siguiente  ir al registro: La búsqueda tardó 0.00 segundos. 
14.
8 p, 1.1 MB Oncological care organisation during COVID-19 outbreak / Onesti, Concetta Elisa (University of Liège. Giga Research Institute) ; Rugo, Hope S. (University of California San Francisco. Department of Medicine) ; Generali, Daniele (University of Trieste) ; Peeters, Marc (University Hospital Antwerp (Bèlgica)) ; Zaman, Khalil (CHUV-Centre Hospitalier Universitaire Vaudois. Oncology Department) ; Wildiers, Hans (University Hospitals Leuven (Bèlgica)) ; Harbeck, Nadia (Ludwig Maximilians University Hospital) ; Martin, Miguel (Universidad Complutense de Madrid. Departamento de Medicina) ; Cristofanilli, Massimo (Northwestern University) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Tjan-Heijnen, Vivianne (Maastricht University Medical Center) ; Hurvitz, Sara A. (University of California Los Angeles) ; Berchem, Guy (Centre Hospitalier de Luxembourg. Hemato-Oncology Department) ; Tagliamento, Marco (Ospedale Policlinico San Martino) ; Campone, Mario (Institut de Cancérologie de l'Ouest. Centre René Gauducheau) ; Bartsch, Rupert (Medical University of Vienna) ; De Placido, Sabino (Università Degli Studi di Napoli Federico II.) ; Puglisi, Fabio (Centro di Riferimento Oncologico) ; Rottey, Sylvie (Uz Gent) ; Müller, Volkmar (University Medical Center Hamburg-Eppendorf) ; Ruhstaller, Thomas (Breast Center of Eastern Switzerland) ; Machiels, Jean-Pascal (Cliniques Universitaires St. Luc) ; Conte, Pierfranco (University of Padova) ; Awada, Ahmad (Université Libre de Bruxelles) ; Jerusalem, Guy (Université de Liège) ; Universitat Autònoma de Barcelona
Background: COVID-19 appeared in late 2019, causing a pandemic spread. This led to a reorganisation of oncology care in order to reduce the risk of spreading infection between patients and healthcare staff. [...]
2020 - 10.1136/esmoopen-2020-000853
ESMO open, Vol. 5 Núm. 4 (august 2020) , p. e000853  
Registro completo - Creative Commons
15.
0 p, 170.6 KB Commentary : SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China / Di Cosimo, Serena (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano) ; Porcu, Luca (Istituto di Ricerche Farmacologiche Mario Negri IRCCS) ; Malfettone, Andrea (Medica Scientia Innovation Research (New Jersey, Estats Units d'Amèrica)) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Miceli, Rosalba (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano. Department of Applied Research and Technological Development) ; Universitat Autònoma de Barcelona
2020 - 10.3389/fonc.2020.01223
Frontiers in Oncology, Vol. 10 (july 2020) , p. 1223  
Registro completo - Creative Commons
16.
9 p, 1.7 MB Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design / Sampayo-Cordero, Miguel (Medica Scientia Innovation Research (MedSIR)) ; Miguel-Huguet, Bernat (Hospital Universitari de Bellvitge) ; Pérez-García, José (QuironSalud Group) ; Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Guerrero-Zotano, Ángel L. (Vanderbilt University Medical Center) ; Garde-Noguera, Javier (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Aguirre, Elena (Hospital Quirónsalud Zaragoza) ; Holgado, Esther (Hospital Universitario Ramón y Cajal (Madrid)) ; López-Miranda, Elena (Hospital Universitario Ramón y Cajal (Madrid)) ; Huang, Xin (Pfizer Global Research and Development) ; Malfettone, Andrea (Medica Scientia Innovation Research (MedSIR)) ; Llombart-Cussac, Antonio (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Non-inferiority (NI) analysis is not usually considered in the early phases of clinical development. In some negative phase II trials, a post-hoc NI analysis justified additional phase III trials that were successful. [...]
2020 - 10.1016/j.conctc.2020.100678
Contemporary Clinical Trials Communications, Vol. 20 (november 2020)  
Registro completo - Creative Commons
17.
13 p, 6.8 MB Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity / Prat, Aleix (Vall d'Hebron Institut d'Oncologia) ; Adamo, Barbara (Vall d'Hebron Institut d'Oncologia) ; Fan, Cheng (Lineberger Comprehensive Cancer Center, University of North Carolina) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Vidal Losada, Maria (Vall d'Hebron Institut d'Oncologia) ; Galván, Patricia (Vall d'Hebron Institut d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Palmer, Héctor G. ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Dawood, Shaheenah (Department of Medical Oncology, Dubai Hospital) ; Rodón, Jordi (Vall d'Hebron Institut d'Oncologia) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ; Campo, Josep Maria Del (Vall d'Hebron Institut d'Oncologia) ; Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
To improve our understanding of the biological relationships among different types of cancer, we have characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer types (breast, ovarian, brain, colorectal, lung adenocarcinoma and squamous cell lung cancer). [...]
2013 - 10.1038/srep03544
Scientific reports, Vol. 3 (december 2013)  
Registro completo - Creative Commons
18.
14 p, 3.0 MB The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1 / Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Escrivá-de-Romaní, Santiago (Hospital Universitari Vall d'Hebron) ; Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ; Luque, Antonio (Vall d'Hebron Institut d'Oncologia) ; Escorihuela, Marta (Vall d'Hebron Institut d'Oncologia) ; Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Dijcks, Fred A. (Preclinical R&D, The Netherlands) ; Dokter, Wim H. A. (Preclinical R&D, The Netherlands) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Saura, Cristina (Hospital Universitari Vall d'Hebron) ; Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. [...]
2020 - 10.3390/cancers12030670
Cancers, Vol. 12 (march 2020)  
Registro completo - Creative Commons
19.
12 p, 615.6 KB ESMO Management and treatment adapted recommendations in the COVID-19 era : Breast Cancer / Azambuja, Evandro de (Institut Jules Bordet and l'Université Libre de Bruxelles) ; Trapani, Dario (European Institute of Oncology) ; Loibl, Sibylle (GBG Forschungs GmbH) ; Delaloge, Suzette (Gustave Roussy and Paris-Saclay University) ; Senkus, Elzbieta (Department of Oncology and Radiotherapy. Medical University of Gdańsk) ; Criscitiello, Carmen (European Institute of Oncology) ; Poortman, Philip (Iridium Kankernetwerk and University of Antwerp) ; Gnant, Michael (Comprehensive Cancer Center. Medical University of Vienna) ; Di Cosimo, Serena (Fondazione IRCCS Istituto Nazionale Dei Tumori) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Cardoso, Fatima (Champalimaud Clinical Center) ; Paluch-Shimon, Shani (Shaare Zedek Medical Centre) ; Curigliano, Giuseppe (Department of Oncology and Hemato-Oncology. University of Milano) ; Universitat Autònoma de Barcelona. Departament de Medicina
The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. [...]
2020 - 10.1136/esmoopen-2020-000793
ESMO open, Vol. 5 (20 2020) , p. e000793  
Registro completo - Creative Commons
20.
30 p, 7.5 MB The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer / De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ; Sammut, Stephen-John (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Ross, Edith M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Bashford-Rogers, Rachael (Department of Medicine. University of Cambridge) ; Greenstein, Erez (Weizmann Institute of Science (Israel). Department of Immunology) ; Markus, Havell (Mayo Clinic Center for Individualized Medicine) ; Morganella, Sandro (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Teng, Yvonne (Cancer Molecular Diagnosis Laboratory. NIHR Cambridge Biomedical Research Centre) ; Maruvka, Yosef (Massachusetts General Hospital (Boston)) ; Pereira, Bernard (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Rueda, Oscar M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Chin, Suet-Feung (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Contente-Cuomo, Tania (Mayo Clinic Center for Individualized Medicine) ; Mayor, Regina (Centro de Investigación Biomédica en Red de Cáncer) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Ali, H. Raza (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Cope, Wei (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Tiezzi, Daniel (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Dariush, Aliakbar (Institute of Astronomy. University of Cambridge) ; Dias Amarante, Tauanne (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Reshef, Dan (Weizmann Institute of Science (Israel). Department of Immunology) ; Ciriaco, Nikaoly (Hospital Universitari Vall d'Hebron) ; Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Vassiliou, George (Wellcome Trust/MRC Cambridge Stem Cell Institute) ; Getz, Gad (Massachusetts General Hospital (Boston)) ; Nik-Zainal, Serena (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Murtaza, Muhammed (Mayo Clinic Center for Individualized Medicine) ; Friedman, Nir (Weizmann Institute of Science (Israel). Department of Immunology) ; Markowetz, Florian (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Caldas, Carlos (Cancer Research UK Cambridge Cancer Centre (Regne Unit)) ; Universitat Autònoma de Barcelona
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. [...]
2019 - 10.1016/j.celrep.2019.04.098
Cell reports, Vol. 27 Núm. 9 (28 2019) , p. 2690-2708.e10  
Registro completo - Creative Commons
21.
14 p, 4.6 MB Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases / De Mattos-Arruda, Leticia (Memorial Sloan Kettering Cancer Center) ; Ng, Charlotte K. Y. (Department of Biomedicine, University of Basel, Basel, Switzerland) ; Piscuoglio, Salvatore (University Hospital Basel (Basilea, Suïssa)) ; Gonzalez-Cao, Maria (Grup Quirónsalud (Barcelona, Catalunya)) ; Lim, Raymond S. (Memorial Sloan Kettering Cancer Center) ; De Filippo, Maria R. (Memorial Sloan Kettering Cancer Center) ; Fusco, Nicola (Memorial Sloan Kettering Cancer Center) ; Schultheis, Anne M. (Memorial Sloan Kettering Cancer Center) ; Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ; Viteri, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Macedo, Gabriel S. (Memorial Sloan Kettering Cancer Center) ; Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ; Gómez, Patricia (Vall d'Hebron Institut d'Oncologia) ; Teixidó, Cristina (Grup Quirónsalud (Barcelona, Catalunya)) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Tresserra Casas, Francesc (Grup Quirónsalud (Barcelona, Catalunya)) ; Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ; Cortés, Javier (Universitat Autònoma de Barcelona. Departament de Medicina) ; Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats) ; Reis-Filho, Jorge S. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. [...]
2018 - 10.18632/oncotarget.25041
Oncotarget, Vol. 9 (april 2018) , p. 20617-20630  
Registro completo - Creative Commons
22.
8 p, 473.7 KB RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer / Cruz, C. (Vall d'Hebron Institut d'Oncologia) ; Castroviejo-Bermejo, Marta (Experimental Therapeutics Group) ; Gutiérrez-Enríquez, Sara (Oncogenetics Group) ; Llop-Guevara, A. (Experimental Therapeutics Group) ; Ibrahim, Y. H. (Experimental Therapeutics Group) ; Gris-Oliver, Albert. (Experimental Therapeutics Group) ; Bonache, Sandra (Oncogenetics Group) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Bruna, Alejandra (Cancer Research UK Cambridge Institute. University of Cambridge) ; Rueda, O. M. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Lai, Z. (AstraZeneca (USA)) ; Polanska, U. M. (Cancer Research UK. Cambridge Institute) ; Jones, G. N. (Cancer Research UK. Cambridge Institute) ; Kristel, P. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; de Bustos, L. (Experimental Therapeutics Group) ; Guzmán, Marta (Experimental Therapeutics Group) ; Rodríguez, O. (Experimental Therapeutics Group) ; Grueso, Judit (Experimental Therapeutics Group) ; Montalban, G. (Oncogenetics Group) ; Caratù, Ginevra (Cancer Genomics Group) ; Mancuso, Francesco M (Cancer Genomics Group) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ; Howat, W. J. (Cancer Research UK. Cambridge Institute) ; Dougherty, B. (AstraZeneca (USA)) ; Vivancos, A. (Cancer Genomics Group) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Serres-Créixams, X. (Department of Radiology) ; Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ; Oaknin, Ana (Vall d'Hebron Institut d'Oncologia) ; Cadogan, E. (Cancer Research UK. Cambridge Institute) ; Barrett, J. Carl (AstraZeneca (USA)) ; Caldas, Carlos (NIHR Cambridge Biomedical Research Centre (Regne Unit)) ; Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Jonkers, Jos (Cancer Genomics Group) ; Diez, Orland (Hospital Universitari Vall d'Hebron) ; O'Connor, M. J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ; Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210  
Registro completo - Creative Commons
23.
10 p, 3.3 MB Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts / Morancho, Beatriz (Hospital Universitari Vall d'Hebron) ; Zacarías-Fluck, Mariano F (Hospital Universitari Vall d'Hebron) ; Esgueva, Antonio (Hospital Universitari Vall d'Hebron) ; Bernadó Morales, Cristina (Hospital Universitari Vall d'Hebron) ; Cosimo, Serena Di (Division of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy) ; Prat, Aleix (Hospital Universitari Vall d'Hebron) ; Cortés, Javier (Hospital Universitari Vall d'Hebron) ; Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Rubio, Isabel T. (Hospital Universitari Vall d'Hebron)
The pleiotropic cytokine IL-6 accelerates the progression of breast cancer in a variety of preclinical models through the activation of the STAT3 (signal transducer and activator of transcription 3) signaling pathway. [...]
2016 - 10.18632/oncotarget.11815
Oncotarget, Vol. 7 (september 2016) , p. 67956-67965  
Registro completo - Creative Commons

Artículos : Encontrados 30 registros   inicioanterior14 - 23siguiente  ir al registro:
Vea también: autores con nombres similares
1 Cortes, J
3 Cortes, J.
42 Cortes, Javier
9 Cortes, Javier,
9 Cortes, Jordi
1 Cortès, Jacques
1 Cortés, J
3 Cortés, J.
9 Cortés, Javier,
9 Cortés, Jordi
1 Cortés, Juan
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos